GlassScriptPhysician profile
Gary B Gulish
NPI 1376572131
$11,819.57
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,664 · 2020: $2,324 · 2021: $2,791 · 2022: $2,820 · 2023: $1,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,220.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,250.19 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $1,933.63 | 2019-2023 | Ozempic, Rybelsus, Saxenda |
| Lilly USA, LLC | $959.39 | 2019-2023 | Mounjaro, Reyvow, Emgality |
| Janssen Pharmaceuticals, INC | $624.41 | 2019-2022 | |
| Abbvie INC. | $613.37 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.32 | 2019-2023 | Synjardy, Jardiance |
| Pfizer INC. | $542.12 | 2019-2023 | |
| Amgen INC. | $479.32 | 2019-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $361.95 | 2019-2022 | |
| Glaxosmithkline, LLC. | $358.55 | 2019-2023 | Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $326.89 | 2019-2022 | |
| Mylan Specialty L.P. | $308.38 | 2019-2023 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $297.25 | 2019-2023 | Seglentis, Livalo |
| Sanofi-Aventis U.S. LLC | $198.06 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $194.82 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gulish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.